Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

Erlotinib (Tarceva™, OSI-774), a potent epidermal growth factor receptor tyrosine kinase inhibitor (EGFR), was evaluated in a phase II study to assess its activity in patients with metastatic colorectal cancer. In all, 38 patients with metastatic colorectal cancer were treated with erlotinib at a co...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Townsley, C A, Major, P, Siu, L L, Dancey, J, Chen, E, Pond, G R, Nicklee, T, Ho, J, Hedley, D, Tsao, M, Moore, M J, Oza, A M
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2006
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2361254/
https://ncbi.nlm.nih.gov/pubmed/16570047
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603055
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi